These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 35708787)
1. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. Masui K; Stöhr T; Pesic M; Tonai T J Anesth; 2022 Aug; 36(4):493-505. PubMed ID: 35708787 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. Zhou J; Leonowens C; Ivaturi VD; Lohmer LL; Curd L; Ossig J; Schippers F; Petersen KU; Stoehr T; Schmith V J Clin Anesth; 2020 Nov; 66():109899. PubMed ID: 32585566 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Schüttler J; Eisenried A; Lerch M; Fechner J; Jeleazcov C; Ihmsen H Anesthesiology; 2020 Apr; 132(4):636-651. PubMed ID: 31972655 [TBL] [Abstract][Full Text] [Related]
5. Time-to-Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia. Lohmer LL; Schippers F; Petersen KU; Stoehr T; Schmith VD J Clin Pharmacol; 2020 Apr; 60(4):505-514. PubMed ID: 31989598 [TBL] [Abstract][Full Text] [Related]
6. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children. Gao YQ; Ihmsen H; Hu ZY; Sun W; Fang YB; Wang Z; Schüttler J; Jeleazcov C; Liu HC Br J Anaesth; 2023 Nov; 131(5):914-920. PubMed ID: 37739904 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. Doi M; Hirata N; Suzuki T; Morisaki H; Morimatsu H; Sakamoto A J Anesth; 2020 Aug; 34(4):491-501. PubMed ID: 32303884 [TBL] [Abstract][Full Text] [Related]
9. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. Chen X; Sang N; Song K; Zhong W; Wang H; Jiang J; Huang Y; Hu P Clin Ther; 2020 Apr; 42(4):614-624. PubMed ID: 32178858 [TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Sheng XY; Liang Y; Yang XY; Li LE; Ye X; Zhao X; Cui YM Eur J Clin Pharmacol; 2020 Mar; 76(3):383-391. PubMed ID: 31873765 [TBL] [Abstract][Full Text] [Related]
11. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555 [TBL] [Abstract][Full Text] [Related]
12. Factors affecting prolonged time to extubation in patients given remimazolam. Shimamoto Y; Sanuki M; Kurita S; Ueki M; Kuwahara Y; Matsumoto A PLoS One; 2022; 17(5):e0268568. PubMed ID: 35584094 [TBL] [Abstract][Full Text] [Related]
13. Up-down determination of the 90% effective dose (ED90) of remimazolam besylate for anesthesia induction. Lu Z; Zhou N; Li Y; Yang L; Hao W Ann Palliat Med; 2022 Feb; 11(2):568-573. PubMed ID: 35249335 [TBL] [Abstract][Full Text] [Related]
14. Determination of the 95% effective dose of remimazolam to achieve loss of consciousness during anesthesia induction in different age groups. Oh J; Park SY; Lee SY; Song JY; Lee GY; Park JH; Joe HB Korean J Anesthesiol; 2022 Dec; 75(6):510-517. PubMed ID: 35912426 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Stöhr T; Colin PJ; Ossig J; Pesic M; Borkett K; Winkle P; Struys MMRF; Schippers F Br J Anaesth; 2021 Sep; 127(3):415-423. PubMed ID: 34246461 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia. Dai G; Pei L; Duan F; Liao M; Zhang Y; Zhu M; Zhao Z; Zhang X Minerva Anestesiol; 2021 Oct; 87(10):1073-1079. PubMed ID: 34263581 [TBL] [Abstract][Full Text] [Related]
17. Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxidoreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers. Hu K; Xiang Q; Wang Z; Sheng X; Li L; Liang Y; Zhao X; Ye X; Cui Y Clin Pharmacol Drug Dev; 2021 Jan; 10(1):22-29. PubMed ID: 32250057 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Remimazolam in Procedural Sedation With Nonhomogeneously Mixed Arterial and Venous Concentrations. Zhou J; Curd L; Lohmer LL; Ossig J; Schippers F; Stoehr T; Schmith V Clin Transl Sci; 2021 Jan; 14(1):326-334. PubMed ID: 33045130 [TBL] [Abstract][Full Text] [Related]
19. [Effective dose and adverse reactions analysis of Remimazolam for sedation in elderly patients undergoing gastroscopy]. Sun H; Wang T; Xu ZX; Chen XF; Cao JB; Li H Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(5):332-335. PubMed ID: 35092973 [No Abstract] [Full Text] [Related]
20. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials. Pesic M; Stöhr T; Ossig J; Borkett K; Donsbach M; Dao VA; Webster L; Schippers F Drugs R D; 2020 Sep; 20(3):267-277. PubMed ID: 32757149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]